Naše izkušnje z zdravilom bevacizumab v primarnem zdravljenju epitelijskega raka jajčnikov

Erik Škof; Dušan Mangaroski

doi:10.25670/oi2020-003on

Authors

Erik Škof Institute of Oncology Ljubljana
Dušan Mangaroski Institute of Oncology Ljubljana

DOI:

https://doi.org/10.25670/oi2020-003on

Keywords:

bevacizumab, epithelial ovarian cancer, adverse events, efficacy

Abstract

Izhodišče: Zdravilo bevacizumab uporabljamo v sklopu primarnega sistemskega zdravljenja napredovalega epitelijskega raka jajčnikov v kombinaciji s paklitakselom in karboplatinom od leta 2013.
Namen: Prikazati učinkovitost in varnost zdravljenja z bevacizumabom v redni klinični praksi v sklopu primarnega zdravljenja raka jajčnikov.
Metode: V retrospektivno analizo smo vključili bolnice z epitelijskim rakom jajčnikov, ki so pričele zdravljenje z bevacizumabom na Onkološkem inštitutu Ljubljana v obdobju 1.1.2013 – 31.12.2016. Cilja raziskave sta bila varnost in učinkovitost (preživetje brez ponovitve bolezni, celokupno preživetje) zdravljenja z bevacizumabom. Raziskavo je odobrila etična komisija na Onkološkem Inštitutu Ljubljana.
Rezultati: V opazovanem obdobju je bilo z bevacizumabom zdravljenih 111 bolnic z napredovalim epitelijskim rakom jajčnikov. Najpogostejši neželeni učinki so bili: bolečine (52%), krvavitev (45%), arterijska hipertenzija (44%). Resne neželene učinke (stopnja 3/4) je imelo 12% bolnic: 3% venska tromboza/embolija, 3% proteinurija, 2% arterijska hipertenzija, 2% krvavitev, 1% bolečine, 1% fistula. Mediani čas sledenja je bil 59 mesecev. Mediano preživetje brez ponovitve bolezni je bilo 18 mesecev, mediano celokupno preživetje je bilo 41 mesecev.
Zaključki: Zdravljenje z bevacizumabom v redni klinični praksi je varno in učinkovito - v skladu z do sedaj znanimi rezultati prospektivnih raziskav GOG 218 in ICON 7.

Abstract (Eng)

Introduction: Bevacizumab is used in advanced epithelial ovarian cancer patients as a part of standard primary sistemic therapy together with paclitaksel and carboplatin combination chemotherapy since 2013.
Aim of study: To evaluate safety and efficacy of bevacizumab in treatment of patients with advanced epithelial ovarian cancer in daily clinical practice.
Methods: Retrospective analysis of patients with advanced epithelial cancer treated with bevacizumab at Institute of Oncology Ljubljana in the period of Jan 1^st 2013 – Dec 31^th 2016. The end points of study were safety and efficacy (relapse-free survival, overall survival). Study has been approved by our institutional ethic board.
Results: In the observed period overall 111 patients with advanced epithelial ovarian cancer were treated with bevacizumab. The most common adverse events were: pain (52%), bleeding (45%), arterial hypertension (44%). Serious adverse events (grade 3/4) were observed in 12% of patients: 3% venous thrombosis/embolism, 3% proteinuria, 2% arterial hypertension, 2% bleeding, 1% pain, 1% fistula. Median follow up was 59 months. Median progression-free survival was 18 months, median overall survival was 41 months.
Conclusions: Treatment with bevacizumab in daily clinical practice is safe and effective – in concordance with published data from prospective studies GOG 218 and ICON 7.